choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Ankylosing Spondylitis Drugs

Ankylosing Spondylitis Drugs Newsletter
  • FDA Approves Another Interchangeable Biosimilar Drug 22 Oct 2021 05:19 GMT

    … be implemented at the pharmacy level.  The approval … active psoriatic arthritis, active ankylosing spondylitis, moderately to severely active … help increase access to treatment options for patients … high-quality, affordable medications that are proven to …

  • Discovery could lead to new treatments for axial spondyloarthritis 21 Oct 2021 02:29 GMT

    … lead to new treatments for axial spondyloarthritis (SpA), a … quot;Although several treatments including biologic drugs have been approved … respond to any treatments and develop severe pain and … to other currently available treatments." Source: Journal …

  • Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo 20 Oct 2021 12:26 GMT

    … the US Food and Drug Administration (FDA) of Boehringer Ingelheim … increase access to treatment options for patients … high-quality, affordable medications that are proven to … rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, …

  • FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira 19 Oct 2021 13:58 GMT

    … S. Food and Drug Administration (FDA) approved Boehringer … meaningful clinical differences for pharmacokinetics, efficacy, immunogenicity, … increase access to treatment options for … psoriatic arthritis, active ankylosing spondylitis, moderately to severely …

  • FDA Deems Adalimumab Biosimilar Cyltezo Interchangeable 18 Oct 2021 19:56 GMT

    … drug, its manufacturer Boehringer Ingelheim announced Oct. 18. The FDA … psoriatic arthritis, ankylosing spondylitis, Crohn' … additional clinical trial in … pharmacokinetics, efficacy, immunogenicity, and safety between the switching and continuous treatment …

  • FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira 18 Oct 2021 14:37 GMT

    … Drug Administration approved the first interchangeable biosimilar product to treat … arthritis; active ankylosing spondylitis (an arthritis that … organism, include medications for treating many serious … pharmacy-level substitution” — similar to how generic drugs …

  • Pfizer's Abrocitinib Receives Positive CHMP Opinion For Atopic Dermatitis Treatment 15 Oct 2021 12:14 GMT

    … ) inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis … daily, for the treatment of adults with active ankylosing spondylitis (AS) who have …

  • Why you should buy AbbVie Inc. shares 23 Oct 2021 21:13 GMT

    … NYSE: ABBV) is Big Pharma multinational, that was spun- … arthritis, psoriatic arthritis and ankylosing spondylitis under rheumatology; atopic dermatitis … in second line of treatment (30 per cent share … portfolio in mid-stage development and it expects improved …

  • Discovery of a potential new therapy for inflammatory arthritis 20 Oct 2021 22:52 GMT

    … “Although several treatments including biologic drugs have been … to any treatments and develop severe pain … other currently available treatments.” Competing Interests Dr … Spondyloarthritis Research and Treatment Network (SPARTAN), and Spondyloarthritis …

  • Global Celecoxib Market 2021 Industry Growth Estimate, Key Players Analysis, Gross Margins, Strategy, Application, Investment Plan, Opportunity and 2030 Forecast 20 Oct 2021 11:45 GMT

    … anti-inflammatory drug. It is used to treat the pain … and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, … Mylan • Chengdu Suncadia Pharmaceutical • Jiangsu Chiatai Qingjiang Pharmaceutical • Anhui Heyi Chemical …

Satisfied with the content?

Continue to create your account.